
|Videos|August 28, 2014
The DUO Trial: IPI-145 vs Ofatumumab in Relapsed or Refractory CLL or SLL
Author(s)Julian Adams, PhD
Julian Adams, PhD, president, Research and Development, Infinity Pharmaceuticals, discusses the rationale behind the DUO trial.
Advertisement
Clinical Pearls
Julian Adams, PhD, president, Research and Development, Infinity Pharmaceuticals, discusses the rationale behind the DUO trial.
- In this phase III trial, IPI-145 is being compared with ofatumumab in patients with relapsed or refractory CLL or SLL.
- This trial is being conducted based on high nodal responses seen in a phase I trial.
- IPI-145 has elicited responses in patients with the 17p deletion, a group that typically has a poor prognosis.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Early Relapse Guides Use of CAR T vs Other Options in LBCL
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5








































